Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Readiness Questioned In Electronic AER Comments

This article was originally published in The Tan Sheet

Executive Summary

FDA's planned move to mandatory electronic filing of adverse event reports is raising concerns about costs for small businesses and the agency's ability to fully integrate its growing number of electronic filing requirements

You may also be interested in...



CHPA comments on OTCs in AER submission rule

The Consumer Healthcare Products Association says FDA's proposed rule concerning mandatory requirements for electronic submission for postmarketing safety reports on drugs and biological products should extend to nonprescription and OTC monograph drugs in addition to OTCs marketed with approved applications, the group said Nov. 10 (1"The Tan Sheet" Aug. 24, 2009). FDA's Aug. 21 posting in the Federal Register proposes OTCs marketed with approved applications, whether with a new drug application and abbreviated new drug application, comply with the rule, and asked for comments on whether OTCs not marketed with approval applications should be subject to the same electronic submission requirements for adverse event reports

Final Guidance For Reporting Adverse Events Gets Serious On Definitions

A report of emergency room treatment connected to use of a dietary supplement may not connote a serious adverse event, FDA says in the final guidance on the reporting and recordkeeping of AE information for supplements

People In Brief

Perrigo promotes in pricing, planning

Topics

UsernamePublicRestriction

Register

PS103774

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel